Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.